The effects of BRL 38227 on antigen-induced extravasation and cellular infiltration into the peritoneal cavity of actively sensitised rats.
The ability of the potassium channel activator cromakalim to relax smooth muscle of the airways is now well established. The compound has been shown to be an effective bronchodilator in animal models, and more importantly, to attenuate induced bronchoconstriction and nocturnal asthma in man. Evidence now exists to suggest that BRL 38227, the 3S,4R enantiomer of cromakalim, is the predominantly active moiety and shares the same profile of activity. Further evaluation of BRL 38227 in a rat model of active peritoneal anaphylaxis provides evidence that potassium channel activators may exert beneficial effects in terms of inhibition of extravasation and inflammatory cell infiltration.
Buckle
D R
DR
SmithKline Beecham Pharmaceuticals, Epsom, Surrey, England.
Taylor
J F
JF
D000284:Administration, Oral; D000818:Animals; D000941:Antigens / Q000276:immunology*; D001578:Benzopyrans / Q000494:pharmacology; D002465:Cell Movement; D019806:Cromakalim; D007114:Immunization; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D009504:Neutrophils / Q000502:physiology*; D010529:Peritoneal Cavity / Q000473:pathology*; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats
D000941:Antigens; D001578:Benzopyrans; D011758:Pyrroles; D019806:Cromakalim